Companies /Healthcare

Acadia Pharmaceuticals Inc

NASDAQ: ACAD Biotechnology
$17.11
▼ $0.48 (−2.73%) today
Markets closed · 9:40pm ET

24/7 Wall St. View

ACAD at a Glance

Valuation
Market cap
$3.0B
P/E ratio
8.3
Profitability
Revenue (TTM)
$1.2B
Profit margin
30.1%
EPS (TTM)
$2.12
Price
52-week range
$16 – $31
24/7 target
$29.46
Street target
$30.21

Headquartered in San Diego, CA Fiscal year ends December NASDAQ: ACAD acadia.com

About Acadia Pharmaceuticals

Acadia Pharmaceuticals is a commercial-stage biopharmaceutical company focused on underserved neurological and rare disease communities. Its revenue comes from net product sales of two drugs.

- **NUPLAZID (pimavanserin):** a selective serotonin inverse agonist and antagonist targeting 5-HT2A receptors. The FDA approved it in 2016 for hallucinations and delusions associated with Parkinson's disease psychosis.
- **DAYBUE (trofinetide):** a synthetic version of the tripeptide GPE. The FDA approved it in 2023 for Rett syndrome in patients aged two and older.

Trofinetide is marketed in several forms and regions:
- As DAYBUE and DAYBUE STIX in the U.S.
- As DAYBUE in Canada.
- As DAYBU in the European Union, following European Commission approval in August 2026 and a German launch in October 2026.

Acadia is pursuing a distribution partner for trofinetide in Japan after completing a Phase 3 study there, with a regulatory filing targeted for 2027.

The pipeline includes:
- Remlifanserin, advancing to Phase 3 in Alzheimer's disease psychosis and in Phase 2 for Lewy body dementia psychosis, where it holds FDA Fast Track designation.
- ACP-211, in Phase 2 for major depressive disorder.
- Earlier-stage programs. Updated

Latest Activity

ACADAcadia Pharmaceuticals
Q3 2026
EPS
$0.31
est $0.18+69.9%
Revenue
$342M
est $333M+2.9%

DAYBUE net sales jumped 39% to $140.1 million on STIX uptake, enough for management to raise full-year guidance for the drug to $505 million to $520 million. Both franchises beat expectations.

Quarterly EPS — reported vs estimate

ACAD Coverage

Frequently Asked Questions

What does Acadia Pharmaceuticals do?

Acadia Pharmaceuticals is a commercial-stage biopharmaceutical company focused on underserved neurological and rare disease communities. Its revenue comes from net product sales of two drugs. - **NUPLAZID (pimavanserin):** a selective serotonin inverse agonist and antagonist targeting 5-HT2A receptors.

What is the ACAD stock price target?

24/7 Wall St.'s 12-month price target for ACAD is $29.46, rated Buy. The Wall Street consensus target is $30.21. ACAD price prediction →